GlassScriptPhysician profile
Robert O Satriale
NPI 1154321719
$7,169.06
in general payments reported to CMS, 2019-2025
37 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,015 · 2020: $1,469 · 2021: $2,535 · 2022: $254 · 2023: $158 · 2024: $492 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,289.57 | 2019-2024 | Tezspire |
| Glaxosmithkline, LLC. | $772.78 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $507.12 | 2019-2024 | Opsumit, Uptravi |
| Insmed, INC. | $459.79 | 2019-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.31 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $426.53 | 2019-2021 | |
| Harmony Biosciences LLC | $367.89 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $329.08 | 2019-2024 | |
| Mylan Specialty L.P. | $279.15 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $221.90 | 2019-2022 | |
| Inspire Medical Systems, INC. | $216.16 | 2024-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $209.41 | 2020-2021 | |
| Grifols USA, LLC | $165.18 | 2019-2021 | |
| Viatris Specialty LLC | $144.53 | 2025 | Yupelri |
| United Therapeutics Corporation | $134.99 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $134.78 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $132.56 | 2019-2022 | |
| Genzyme Corporation | $124.73 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $119.15 | 2019 | |
| Advanced Respiratory, INC | $102.08 | 2020-2021 | |
| Philips North America LLC | $94.91 | 2019-2021 | |
| Pfizer INC. | $54.81 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $49.88 | 2019-2020 | |
| Csl Behring | $49.52 | 2019 | |
| Resmed Corp | $40.88 | 2020-2021 | |
| Shire North American Group INC | $39.09 | 2019 | |
| Biomerieux INC | $30.01 | 2020 | |
| Circassia INC. | $29.35 | 2019-2020 | |
| Eisai INC. | $27.90 | 2021 | |
| Mallinckrodt Hospital Products INC. | $27.23 | 2020 | |
| Pulmonx Corporation | $23.56 | 2023 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Tactile Systems Technology INC | $21.91 | 2024 | Entre Plus, Flexitouch Plus |
| Vifor Pharma, INC. | $20.14 | 2024 | Zemaira |
| Paratek Pharmaceuticals, INC. | $18.00 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $17.61 | 2024 | Lumryz |
| Nabriva Therapeutics, Plc | $17.11 | 2021 | |
| Amgen INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Satriale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.